Today's PR was the announcement of the VRTX all-oral strategy. Glad - I know you and several others were looking for this type of PR and hoping it would pop the pps a bit. Well, it didn't. Wish I we're wrong, but I knew this type of PR was useless to the pps.
The PPS went up more than the general market but I expected a better close.
I think investors and analysts who do not keep up with details such as the old and new reported timelines for drug trials may not have noticed the change in the announced timelines (I wrote about the change in my earlier post).
I think an interim data report on all oral 222+Incivek+Riba, if good, could have moved the PPS a lot better than today.
As for the future, the release of the 7 day data on Alios compounds, if good, may move the pps. At least it did for INHX. We will have to wait and see.
It is possible that for a while regardless of what VRTX does the shorts may be in total control and only patient investors will be rewarded with this stock once the shorts decide to exit their position or if VRTX is taken over because it is so cheap now.
After the kind of beating Vertex stock took, it is going to take a lot of positive news to bring the pps up in a significant way. Fortunately, there could be good news coming for Vertex over the next several months: results of trials of Incivek/VX222/ribavirin, Q4 revenues/earnings, approval of Kalydeco in April, results of phase I Alios nucs. Hopefully, these will all be positive news events.
The most important interim data in the first 6 months of 2012 may be the Phase 2 CF combination study with VX 809 and 770. which if positive, would open the door to a revenue stream for Vertex that could exceed the potential of hepatitis C over the next ten to 15 years for Vertex.